Incidence and predictors of activation syndrome induced by antidepressants

Depression and Anxiety

Volumn 25, Issue 12, 2008, Pages 1014-1019

  Harada, Tsuyoto ^a   Sakamoto, Kaoru ^a   Ishigooka, Jun ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Activation syndrome; Adverse effect; Antidepressant; SSRI; Suicide

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOMIPRAMINE; DOSULEPIN; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MILNACIPRAN; NORTRIPTYLINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ACTIVATION SYNDROME; ADULT; AGED; AGGRESSIVENESS; AGITATION; AKATHISIA; ANXIETY; ARTICLE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INDUCED DISEASE; FEMALE; HEALTH SURVEY; HOSTILITY; HUMAN; HYPOMANIA; IMPULSIVENESS; INCIDENCE; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MANIA; OUTPATIENT; PANIC; PERSONALITY DISORDER; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS; AROUSAL; BENZODIAZEPINES; BIPOLAR DISORDER; COMORBIDITY; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; DYSTHYMIC DISORDER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PERSONALITY DISORDERS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; SUICIDE; SUICIDE, ATTEMPTED; YOUNG ADULT;

EID: 57349095508     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20438     Document Type: Article

References (16)

1. Friedman EH. Tricyclic-induced activation/jitteriness. J Clin Psychopharmacol 1991;11:394-395.
2. Jackson CW, Lydiard RB. Two cases of activation/jitteriness associated with TCAs. J Clin Psychopharmacol 1990;10:439-440.
3. Pohl R, Yeragani VK, Ortiz A, Rainey Jr. JM, Gershon S. Response of tricyclic-induced jitteriness to a phenothiazine in two patients. J Clin Psychiatry 1986;47:427.
4. Yeragani VK, Pohl R, Balon R. Tricyclics, akathisia, and jitteriness. J Clin Psychopharmacol 1988;8:295.
5. Yeragani VK, Pohl R, Balon R, Kulkarni A, Keshavan M. Low serum iron levels and tricyclic antidepressant-induced jitteriness. J Clin Psychopharmacol 1989;9:447-448.
6. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210.
7. FDA. Worsening depression and suicidality in patients being treated with antidepressant. 2004. Available at: http://www.fda.gov/CDER/DRUG/ antidepressants/AntidepressanstPHA.htm.
8. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163:41-47.
9. Sakamoto K, Fukunaga T. The impact of attempted suicide on the symptoms and course of mood disorders. J Clin Psychiatry 2003;64:1210-1216.
10. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research; 2002.
11. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington: American Psychiatric Press; 1997.
12. Beasley Jr. CM, Potvin JH. Fluoxetine: activating and sedating effects. Int Clin Psychopharmacol 1993;8:271-275.
13. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994;55:394-400.
14. Pohl R, Yeragani VK, Balon R, Lycaki H. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988;49:100-104.
15. Edwards JG, Inman WHW, Wilton L, Pearce GL, Kubota K. Drug safety monitoring of 12692 patients treated with fluoxetine. Hum Psychopharmacol 1997;12:127-137.
16. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005;330:396.